Liu XP, Wang HB, Yang K, Sui AH, Shi Q, Qu S: Inhibitory effects of adenovirus mediated tandem expression of RhoA and RhoC shRNAs in HCT116 cells. J Exp Clin Cancer Res 2009, 28:52.PubMedCrossRef 20. Hall A: The cellular functions of small Staurosporine GTP-binding proteins. Science (Wash DC) 1990, 249:635–640.CrossRef 21. Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC: Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004, 1705:121–132.PubMed 22. Fiordalisi JJ,

Keller PJ, Cox AD: PRL tyrosine Selleck JAK inhibitor phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 2006, 66:3153–3161.PubMedCrossRef 23. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H: 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002, 122:308–317.PubMedCrossRef 24. Ikoma T, Takahashi T, Nagano S, Li YM, Ohon Y, Ando K, Fujiwara T, Fujiwara H, Kosai K: A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res 2004, 10:1192–1200.PubMedCrossRef 25. Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, Liu

HL: Genomic analysis reveals RhoC as a potential marker in hepatocellular www.selleckchem.com/products/Trichostatin-A.html carcinoma with poor prognosis. Br J Cancer 2004, 90:2349–2355.PubMed 26. Wang H, Chen Y, Cao D, Zhang Y, Meng R, Lu J: RhoA gene expression in colorectal carcinoma. Zhonghua Yi Xue Za Zhi 2002, 82:348–351.PubMed 27. Pille JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, Soria C, Li H: Anti-RhoA

and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005, 11:267–274.PubMedCrossRef 28. Duxbury MS, Whang EE: RNA interference: a practical approach. J Surg Res 2004, 117:339–344.PubMedCrossRef 29. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB: A phase Mirabegron I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000, 6:798–806.PubMed 30. Hubberstey AV, Pavliv M, Parks RJ: Cancer therapy utilizing an adenoviral vector expressing only E1A. Cancer Gene Ther 2002, 9:321–329.PubMedCrossRef 31. Palacios G, Crawford HC, Vaseva A, Moll UM: Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell Cycle 2008, 7:2584–2590.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions WHB and LXP designed the research; YK and SAH carried out the molecular genetic studies; WZB and SQ participated in the nude mice studies; ZG and YRY discussed the results and analyzed data; WHB and LXP wrote the paper. All authors read and approved the final manuscript.